Show simple item record

dc.contributor.authorPatel, Mitesh
dc.contributor.authorArshad, Qadeer
dc.contributor.authorSeemungal, Barry M.
dc.contributor.authorHarcourt, Jonny P.
dc.contributor.authorGolding, John F.
dc.contributor.authorBronstein, Adolfo M.
dc.date.accessioned2019-01-11T11:30:32Z
dc.date.available2019-01-11T11:30:32Z
dc.date.issued2018-02-28
dc.identifier.issn0959-8138en
dc.identifier.doi10.1136/bmj.i6185
dc.identifier.urihttp://hdl.handle.net/2436/622046
dc.description.abstractWe apologise for not having noticed earlier Adrion and colleagues’ comments on our study comparing the effectiveness of intratympanic Methylprednisolone to Gentamicin in refractory Ménière’s disease [1], covered by the BMJ [2]. Contrary to our expectations, both drugs were equally effective in controlling vertigo (primary outcome).en
dc.formatapplication/PDFen
dc.language.isoenen
dc.publisherBritish Medical Journalen
dc.relation.urlhttps://www.bmj.com/content/355/bmj.i6185/rr-0en
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
dc.subjectMeniere's diseaseen
dc.subjectclinical trialen
dc.subjectmethylprednisoloneen
dc.subjectgentamicinen
dc.subjectvertigoen
dc.titleReply to Adrion et al. On Patel et al. Letter to the Editor, British Medical Journalen
dc.typeOtheren
dc.identifier.journalBritish Medical Journalen
pubs.place-of-publicationLondon, UK
dc.date.accepted2018-02-28
rioxxterms.funderUniversity of Wolverhamptonen
rioxxterms.identifier.projectUOW110119MPen
rioxxterms.versionAMen
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/en
rioxxterms.licenseref.startdate2019-01-11en
refterms.dateFCD2019-01-11T11:30:33Z
refterms.versionFCDAM
refterms.dateFOA2019-01-11T11:30:33Z


Files in this item

Thumbnail
Name:
Reply to Adrion BMJ.pdf
Size:
303.9Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 United States
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 United States